摘要
树突状细胞(DC)是最强的抗原递呈细胞,可以激活幼稚T细胞,打破外周免疫耐受,进而诱导肿瘤免疫应答。对于复发或者进展性前列腺癌患者,以DC为基础的免疫治疗可延长患者生存期。本文综述DC疫苗临床治疗研究进展。
Dendritic cell （DC） is the most powerful antigen-presenting cell （APC）, which can prime naive T cell and break peripheral tolerance and thus induce tumor immune responses. DC-based active immunotherapy can extend the survival time of the patients. This review decribes advances in DC-based for vaccine prostate camcer.
出处
《世界临床药物》
CAS
2014年第2期69-73,共5页
World Clinical Drug
